SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure

Ashish Verma; Ankit B Patel; Sushrut S Waikar

doi:10.1016/j.cmet.2020.06.014

SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure

Cell Metab. 2020 Jul 7;32(1):13-14. doi: 10.1016/j.cmet.2020.06.014.

Authors

Ashish Verma¹, Ankit B Patel², Sushrut S Waikar³

Affiliations

¹ Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: [email protected].
² Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
³ Section of Nephrology, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.

PMID: 32640243
DOI: 10.1016/j.cmet.2020.06.014

Abstract

Recent studies have shown impressive cardiovascular health benefits in individuals treated with SGLT2 inhibitors (SGLT2i) regardless of diabetic status. The underlying mechanisms driving these benefits are not well understood. Recently in Circulation, Griffin et al. (2020) reported the first human study investigating the diuretic effect of empagliflozin.

Publication types

Comment

MeSH terms

Benzhydryl Compounds
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Diuretics
Glucosides
Heart Failure* / drug therapy
Humans
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Benzhydryl Compounds
Diuretics
Glucosides
Sodium-Glucose Transporter 2 Inhibitors
empagliflozin